Modern prepare the first pan-respiratory vaccine, which would be able to fight viruses that cause endemic respiratory infections, such as seasonal colds. He was already working on it before the coronavirus pandemic arrived, which, with its arrival, further addressed the issue of performing this type of vaccine. The pharmacist has two development programs.
First, Moderna is preparing a vaccine to attack three of the most significant viruses that cause respiratory diseases in older adults, known so far as mRNA-1230. This vaccine is intended as annual booster dose against him coronavirus, la gripe and RSV.
It also prepares the program to develop a candidate vaccine against endemic human coronaviruses. Although they are less well known, they are an important cause of respiratory diseases. They are responsible for approximately 10% to 30% of infections of the upper respiratory tract in adults.
We are pleased to add a combined respiratory vaccine candidate against three of the leading causes of respiratory disease in older adults, and a vaccine against the four endemic human coronaviruses.
Combine into a single vaccine
Moderna’s goal is to achieve a single vaccine that reduce the chances suffering from this type of respiratory disease. “Our goal is to develop vaccines to tackle respiratory infections and eventually combine many of them into a single annual booster shot,” he concludes.
Respiratory tract infections are a public health problem and target the main causative agents. Coronaviruses, seasonal flu and RSV have a considerable cost to human health, especially in older people. They experience more severe disease and higher mortality than the young.
Moderna is also working to create a vaccine that fights tuberculosis, malaria, and more than just the World Health Organization (WHO) considered more serious.
–
